A study of empasiprubart for chronic inflammatory demyelinating polyneuropathy (CIDP)
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of CIDP (a nerve condition) that is either the typical form or one of these types: motor-predominant, multifocal (Lewis-Sumner), focal, or distal.
- Your CIDP must still be active—meaning you have symptoms that bother you and need treatment.
- You have not tried any CIDP treatment before, or you have stopped your last treatment, or you are currently on a common treatment like steroids, immunoglobulins (IVIG/SCIG), plasma exchange, or an FcRn inhibitor and are willing to switch to the study drug.
- You cannot have a pure sensory form of CIDP or only
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
This trial tests a new drug called DNTH103 for adults with CIDP, a condition that affects nerves and causes weakness. It aims to see if the drug can help people who are currently on treatment, have tried treatment before, or are new to treatment.
This trial tests a new medicine called empasiprubart in teenagers ages 12–17 with CIDP, a rare nerve disease that causes weakness and numbness. Researchers want to find the right dose and see if it safely reduces symptoms.
This trial tests a new drug called Imeroprubart for people with CIDP who are already on a stable treatment like steroids or immunoglobulin. The goal is to see if the drug can help control symptoms better.
This trial tests whether a blood-filtering treatment called immunoadsorption can help people with CIDP. It is for adults who are already receiving or starting IVIg or MP therapy.
Hear when a new Chronic Inflammatory Demyelinating Polyneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.